Undisclosed 1 is under clinical development by Palleon Pharmaceuticals and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Undisclosed 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Undisclosed 1 overview
The therapeutic candidate is under development for the treatment of autoimmune disease.
Palleon Pharmaceuticals overview
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company is headquartered in Waltham, Massachusetts, the US
For a complete picture of Undisclosed 1’s drug-specific PTSR and LoA scores, buy the report here.